NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $5.40 -0.23 (-4.09%) Closing price 04:00 PM EasternExtended Trading$5.40 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Entero Therapeutics Stock (NASDAQ:ENTO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$5.10▼$5.8050-Day Range$1.09▼$5.6352-Week Range$0.97▼$5.83Volume289,893 shsAverage Volume829,874 shsMarket Capitalization$8.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Entero Therapeutics, Inc. (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases. Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations. Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.AI Generated. May Contain Errors. Read More Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTO Stock News HeadlinesEntero Therapeutics (NASDAQ:ENTO) Upgraded at Wall Street ZenOctober 6, 2025 | americanbankingnews.comEntero Therapeutics (NASDAQ:ENTO) Trading 0.2% Higher After Analyst UpgradeOctober 5, 2025 | americanbankingnews.comBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.October 14 at 2:00 AM | Altimetry (Ad)Entero Therapeutics, Inc. (ENTO) Names Jason D. Sawyer as New CEO Amid Strategic ShiftSeptember 25, 2025 | finance.yahoo.comEntero Therapeutics, Inc. (ENTO) Names Jason D. Sawyer as New CEO Amid Strategic ShiftSeptember 23, 2025 | insidermonkey.comEntero Therapeutics Appoints Jason Sawyer as Interim CEOSeptember 9, 2025 | tipranks.comEntero Therapeutics files to sell 4.95M shares of common stock for holdersAugust 26, 2025 | msn.comEntero Therapeutics Inc trading halted, news pendingAugust 16, 2025 | msn.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $1.8660 on January 1st, 2025. Since then, ENTO shares have increased by 183.5% and is now trading at $5.29. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.42) earnings per share (EPS) for the quarter. When did Entero Therapeutics' stock split? Entero Therapeutics's stock reverse split on Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include CDT Equity (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST). Company Calendar Last Earnings8/14/2025Today10/14/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTO Previous SymbolNASDAQ:ENTO CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,063.82% Return on Assets-17.94% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.45) per share Price / Book-2.30Miscellaneous Outstanding Shares1,590,000Free Float1,576,000Market Cap$8.95 million OptionableN/A Beta1.14 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:ENTO) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
